Side Effects and Relative Risks Associated with Subcutaneous and Sublingual Immunotherapy
Allergens/Allergy Testing/Allergy Therapeutics
Sunday, March 4, 2018: 12:30 PM-1:30 PM
Hyatt, Convention Level, Celebration 6
1.00 CME/CE
Primary Discussion Leaders:
Moises A Calderon, MD PhD
Tolly Epstein, MD FAAAAI

Learning Objectives:
  1. Identify patients at highest risk of systemic anaphylaxis or fatal reactions with SCIT and SLIT
  2. Discuss risk reduction strategies for severe anaphylaxis associated with SCIT
  • Handout Session 3506 -TE-MC (30Jan2018).pdf (215.3 kB)
  • See more of: Session